An observational study in Hepatocellular Carcinoma (HCC) and Liver Transplantation (LT), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Carcinoma, Hepatocellular by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 20 under way, 1 of them phase 3. Carcinoma, Hepatocellular · Assistance Publique - Hôpitaux de Paris.
Among the 41 studies in Carcinoma, Hepatocellular by Assistance Publique - Hôpitaux de Paris, this one is the 7th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2026, is one of 15 observational ones, reaches primary completion later than 6 of the 19 other live ones, and was the 40th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →16 of the 41 studies in Carcinoma, Hepatocellular by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–90
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 5
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 562 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 85 across the 26 interventional studies, 372 across the 15 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
5 of the studies in Carcinoma, Hepatocellular by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07629193Assistance Publique - Hôpitaux de ParisLiver Transplant for Hepatocellular Carcinoma | 2027-01 |
| NCT05901194Assistance Publique - Hôpitaux de ParisLenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma | 2027-04 |
| NCT06045975Assistance Publique - Hôpitaux de ParisDurvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure | 2027-09-27 |
| NCT05971628Assistance Publique - Hôpitaux de ParisResection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma | 2027-10 |
| NCT06334965Assistance Publique - Hôpitaux de ParisMulti-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated with Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 41 studies in Carcinoma, Hepatocellular by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This research focuses on analysing data collected as part of your usual care. Currently, the eligibility of patients with hepatocellular carcinoma for liver transplantation is based on the calculation of scores. These scores mainly take into account the volume of the tumour measured by imaging, one or more blood markers and the patient's general condition.
However, these scores do not take into account:
The aim of our study is to develop a new score incorporating these factors in order to identify patients with hepatocellular carcinoma who could truly benefit from a liver transplant.
To answer the question posed in the research, data will be collected from 402 people who received a liver transplant for hepatocellular carcinoma at three hospitals in the Paris region between 1 January 2018 and 31 December 2023, and from 160 people at two international hospitals in Canada and Belgium.
Hepatocellular carcinoma (HCC) is a major public health problem. It is the fifth most common cancer and the third leading cause of cancer death worldwide. Its prevalence continues to increase and mortality associated with HCC remains high, unlike the overall cancer mortality rate. Liver transplantation (LT) remains the only curative treatment option that addresses both the tumour disease and the underlying liver disease. However, this approach presents a major challenge: the occurrence of tumour recurrence after LT, which is highly morbid. Rigorous selection for LT of candidates with HCC is essential and is currently based on standardised scores, such as AFP, Milan or Up to Seven scores, which take into account tumour volume and the patient's general condition prior to LT.
The recent arrival of immunotherapy in the management of advanced HCC has opened up new prospects for LT. In particular, the question arises as to whether LT should be offered to patients initially diagnosed with advanced HCC who have benefited from downstaging treatments, including immunotherapy.
At the same time, due to the shortage of transplants, waiting times on the LT list are getting longer in some countries and patients are increasingly receiving expectant management for their HCC. They are exposed to the risk of HCC progression or recurrence while on the list, ruling out any possibility of subsequent LT. Certain histological subtypes of HCC, particularly macrotrabecular HCC, have recently been identified as being associated with a poor prognosis, but little data is available on the risk of recurrence of these HCCs after LT raising questions about the relevance of LT for these patients.
Finally, the impact of the choice of immunosuppression on the risk of HCC recurrence after LT remains largely unexplored.
Main objective:
In accordance with TRIPOD recommendations (40), the objective is to improve the predictive scores for LT failure in patients with HCC by analysing biological, clinical, imaging and anatomopathological parameters at enrolment. This score will also include the number and type of HCC recurrences, as well as the associated expectant management. The objective is to determine the threshold of predictive score for achieving a probability of LT failure in patients of less than 20%.
Secondary objectives:
We will retrospectively include patients who underwent LT for HCC between 1 January 2018 and 31 December 2023 in the Paris, Montreal and Brussels centres.
The derivation cohort will include patients from the AP-HP, while the validation cohort will include patients from the centres in Montreal and Brussels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Failure of liver transplantation (LT)
Failure of LT is defined as the occurrence of one of the following events: (i) removal from the transplant waiting list, (ii) recurrence of HCC post-LT, or (iii) death.
Time frame: Up to 7 years after LT
Overall survival
Time frame: Up to 7 years after LT
Recurrence-free survival
Time frame: Up to 7 years after LT
Occurrence of acute cellular rejection
Time frame: Up to 7 years after LT
Correlation of LT failure rate, overall survival and recurrence-free survival with biological, clinical, imaging and anatomopathological parameters (macro-trabecular subtype) at enrolment and on the day of LT
Time frame: Up to 7 years after LT
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jan 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →